Eledon Pharmaceuticals (ELDN)

First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
March 22, 2024
Report ID: 26614
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Eledon Pharmaceuticals
Eledon Pharmaceuticals
Healthcare
Biotechnology
Ticker
ELDN
Current Price
$1.59 -3.05%
Market Cap
$39.5M
Price Target
Refer to Report
Volume
10.1K
52wk Range
$1.07 - $2.95
Related Research Reports
3/22/2024

First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection
First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection (ELDN)
11/10/2023

3Q23 Reported With Review Of Clinical Progress
3Q23 Reported With Review Of Clinical Progress (ELDN)
11/3/2023

Phase 1b Data Shows Safety With An Important Improvement In Kidney Function
Phase 1b Data Shows Safety With An Important Improvement In Kidney Function (ELDN)
10/26/2023

C-Suite Interview With Eledon CEO Available On ChannelChek
C-Suite Interview With Eledon CEO Available On ChannelChek (ELDN)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.